Carbidopa; Entacapone; Levodopa Patent Expiration
Carbidopa; Entacapone; Levodopa is Used for managing the symptoms of Parkinson's disease. It was first introduced by Orion Pharma
Carbidopa; Entacapone; Levodopa Patents
Given below is the list of patents protecting Carbidopa; Entacapone; Levodopa, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Stalevo 100 | US6500867 | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 100 | US6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 125 | US6500867 | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 125 | US6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 150 | US6500867 | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 150 | US6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 200 | US6500867 | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 200 | US6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 50 | US6500867 | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 50 | US6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 75 | US6500867 | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 75 | US6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun 29, 2020
(Expired) | Orion Pharma |
| Stalevo 100 | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
| Stalevo 125 | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
| Stalevo 150 | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
| Stalevo 200 | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
| Stalevo 50 | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
| Stalevo 75 | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Carbidopa; Entacapone; Levodopa's patents.
Latest Legal Activities on Carbidopa; Entacapone; Levodopa's Patents
Given below is the list recent legal activities going on the following patents of Carbidopa; Entacapone; Levodopa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 28 Sep, 2004 | US6797732 |
| Patent Issue Date Used in PTA Calculation Critical | 28 Sep, 2004 | US6797732 |
| Issue Notification Mailed Critical | 09 Sep, 2004 | US6797732 |
| Receipt into Pubs | 03 Sep, 2004 | US6797732 |
| Application Is Considered Ready for Issue Critical | 01 Sep, 2004 | US6797732 |
| Dispatch to FDC | 01 Sep, 2004 | US6797732 |
| Issue Fee Payment Received Critical | 18 Aug, 2004 | US6797732 |
| Issue Fee Payment Verified Critical | 18 Aug, 2004 | US6797732 |
| Receipt into Pubs | 17 Aug, 2004 | US6797732 |
| Receipt into Pubs | 07 Jun, 2004 | US6797732 |
Carbidopa; Entacapone; Levodopa's Family Patents
Explore Our Curated Drug Screens
Carbidopa; Entacapone; Levodopa Generic API Manufacturers
Several generic applications have been filed for Carbidopa; Entacapone; Levodopa. The first generic version for Carbidopa; Entacapone; Levodopa was by Sun Pharmaceutical Industries Ltd and was approved on May 10, 2012. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Apr 15, 2025.
Given below is the list of companies who have filed for Carbidopa; Entacapone; Levodopa generic, along with the locations of their manufacturing plants worldwide.
1. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Carbidopa; Entacapone; Levodopa. All of these versions come by the name CARBIDOPA, LEVODOPA AND ENTACAPONE. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG; 200MG; 50MG | tablet | Prescription | ORAL | AB | Apr 15, 2025 |
| 18.75MG; 200MG; 75MG | tablet | Prescription | ORAL | AB | Apr 15, 2025 |
| 25MG; 200MG; 100MG | tablet | Prescription | ORAL | AB | Apr 15, 2025 |
| 31.25MG; 200MG; 125MG | tablet | Prescription | ORAL | AB | Apr 15, 2025 |
| 37.5MG; 200MG; 150MG | tablet | Prescription | ORAL | AB | Apr 15, 2025 |
| 50MG; 200MG; 200MG | tablet | Prescription | ORAL | AB | Apr 15, 2025 |
2. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 6 different strengths of generic version for Carbidopa; Entacapone; Levodopa. All of these versions come by the name CARBIDOPA, LEVODOPA AND ENTACAPONE. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG; 200MG; 50MG | tablet | Discontinued | ORAL | N/A | Aug 13, 2020 |
| 18.75MG; 200MG; 75MG | tablet | Discontinued | ORAL | N/A | Aug 13, 2020 |
| 25MG; 200MG; 100MG | tablet | Discontinued | ORAL | N/A | Aug 13, 2020 |
| 31.25MG; 200MG; 125MG | tablet | Discontinued | ORAL | N/A | Aug 13, 2020 |
| 37.5MG; 200MG; 150MG | tablet | Discontinued | ORAL | N/A | Aug 13, 2020 |
| 50MG; 200MG; 200MG | tablet | Discontinued | ORAL | N/A | Aug 13, 2020 |
3. RISING
Rising Pharma Holdings Inc has filed for 6 different strengths of generic version for Carbidopa; Entacapone; Levodopa. All of these versions come by the name CARBIDOPA, LEVODOPA AND ENTACAPONE. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG; 200MG; 50MG | tablet | Prescription | ORAL | AB | Jan 25, 2022 |
| 18.75MG; 200MG; 75MG | tablet | Prescription | ORAL | AB | Jan 25, 2022 |
| 25MG; 200MG; 100MG | tablet | Prescription | ORAL | AB | Jan 25, 2022 |
| 31.25MG; 200MG; 125MG | tablet | Prescription | ORAL | AB | Jan 25, 2022 |
| 37.5MG; 200MG; 150MG | tablet | Prescription | ORAL | AB | Jan 25, 2022 |
| 50MG; 200MG; 200MG | tablet | Prescription | ORAL | AB | Jan 25, 2022 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
4. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Carbidopa; Entacapone; Levodopa. All of these versions come by the name CARBIDOPA, LEVODOPA AND ENTACAPONE. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG; 200MG; 100MG | tablet | Prescription | ORAL | AB | May 10, 2012 |
| 37.5MG; 200MG; 150MG | tablet | Prescription | ORAL | AB | May 10, 2012 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||
5. WOCKHARDT LTD
Wockhardt Ltd has filed for 6 different strengths of generic version for Carbidopa; Entacapone; Levodopa. All of these versions come by the name CARBIDOPA, LEVODOPA AND ENTACAPONE. Given below are the details of the strengths of this generic introduced by Wockhardt Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG; 200MG; 50MG | tablet | Discontinued | ORAL | N/A | Nov 20, 2012 |
| 18.75MG; 200MG; 75MG | tablet | Discontinued | ORAL | N/A | Nov 20, 2012 |
| 25MG; 200MG; 100MG | tablet | Discontinued | ORAL | N/A | Nov 20, 2012 |
| 31.25MG; 200MG; 125MG | tablet | Discontinued | ORAL | N/A | Nov 20, 2012 |
| 37.5MG; 200MG; 150MG | tablet | Discontinued | ORAL | N/A | Nov 20, 2012 |
| 50MG; 200MG; 200MG | tablet | Discontinued | ORAL | N/A | Nov 20, 2012 |